Document is current
Any future updates will be listed below
-
Authors
Scott, Daniel C.
Chittori, Sagar https://orcid.org/0000-0003-1417-6552
Purser, Nicholas https://orcid.org/0000-0003-2686-2277
King, Moeko T. https://orcid.org/0000-0002-4192-8337
Maiwald, Samuel A. https://orcid.org/0000-0002-7235-2748
Churion, Kelly
Nourse, Amanda https://orcid.org/0000-0003-4595-5321
Lee, Chan https://orcid.org/0000-0002-5512-8146
Paulo, Joao A. https://orcid.org/0000-0002-4291-413X
Miller, Darcie J.
Elledge, Stephen J. https://orcid.org/0000-0001-7923-6283
Harper, J. Wade https://orcid.org/0000-0002-6944-7236
Kleiger, Gary https://orcid.org/0000-0003-3924-1680
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
-
Funding
Funding for this research was provided by:
Max-Planck-Gesellschaft (Schulman department)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5RO1CA247365, CA279255)
U.S. Department of Health & Human Services | National Institutes of Health (GM132129, 01AG11085, GM141409)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 29 October 2024
First Online: 15 November 2024
Competing interests
: D.C.S. and B.A.S. are co-inventors of intellectual property that is unrelated to this work (DCN1 inhibitors licensed to Cinsano). J.W.H. is a founder and consultant for Caraway Therapeutics and is a scientific advisory board member for Lyterian Therapeutics. SJE is a founder of, and holds equity in TScan Therapeutics and Immune ID. S.J.E. is also founder of MAZE Therapeutics, and Mirimus and serves on the scientific advisory board of TSCAN Therapeutics, and MAZE Therapeutics. In accordance with Partners HealthCare’s conflict of interest policies, the Partners Office for Interactions with Industry has reviewed SJE’s financial interest in TSCAN and determined that it creates no significant risk to the welfare of participants in this study or to the integrity of this research. B.A.S. is a member of the scientific advisory boards of Biotheryx and Proxygen. The remaining authors declare no competing interests.
